BD Extends Longstanding Expertise in Diabetes Management to Benefit Pets

New BD U-40 Pet Syringes Available at Veterinary Offices

Apr 26, 2016

FRANKLIN LAKES, N.J., April 26, 2016 – BD (Becton, Dickinson and Company), a leading medical technology company, announced today that it has launched BD Pet Syringes – veterinary insulin syringes for use with U-40 insulins that are administered to dogs and cats with diabetes.

The main treatment to regulate glucose in diabetic pets is the administration of insulin by injection. To address the insulin requirements of pets, BD Pet Syringe was designed with U-40, a smaller concentration insulin, compared to the standard U-100 insulin available for human medicine.

“BD has been committed to improving the lives of people with diabetes for more than 90 years,” said Kenneth Miller, worldwide president of Diabetes Care for BD. “We are delighted to deliver our innovation and quality to pet owners to help ensure that they are giving their pets accurate amounts of insulin, and help their pets with diabetes live healthier lives.”

BD Pet Syringes are available in both 0.5mL and 0.3mL sizes to accommodate various levels of insulin dosing. They feature a red scale mark to distinguish the U-40 insulin syringe from the U-100 insulin syringe, which have black scale marks and half-unit scale markings to help ensure more precise dosing. BD Pet Syringes feature a 12.7mm needle length to accommodate a variety of skin thickness and fur density. The 29 gauge needle helps reduce the risk of bending and breaking should the pet move during injection.

U-40 Veterinary Insulin Syringes are currently available through veterinary offices. Visit for more information.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

For more information on BD, please visit

Lindsay Roman

201 847 4312
Email Lindsay

Back to News Releases

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.